Paid Clinical Trials in Connecticut

Connecticut has 1,306 paid clinical trials enrolling now across cities including New Haven, Hartford and Stamford. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 28, 2026.

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

1,161 clinical trials

↓ Download CSV

A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

for Episodic Migraine

Drug: IPN10200

Sites in Stamford +67 more locations

Sponsor: Ipsen

Sex: All·Age: 18 - 80

Code: NCT06625060·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

Sites in New Haven +51 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Sites in New Haven +57 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136650·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

Drug: daraxonrasib

Sites in New Haven +42 more locations

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

for Lumbar Spinal Stenosis

Sites in New Haven, Hartford +2341 more locations

Sponsor: Stryker Instruments

Sex: All·Age: 18+

Code: NCT03072927·Recruiting·Listed Mar 2017

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

Sites in New Haven +76 more locations

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for Non-Small Cell Lung Cancer

Drug: Telisotuzumab Vedotin

Sites in New Haven +37 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT06568939·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for Endometrial Cancer

Sites in New Haven +45 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06952504·Phase 3·Recruiting·Listed May 2025

Apply to this trial

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

for Chronic Lymphocytic Leukemia

Drug: Nemtabrutinib

Sites in Norwich +42 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136559·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

for Atopic Dermatitis

Drug: Upadacitinib

Sites in New Haven +65 more locations

Sponsor: AbbVie

Sex: All·Age: 18 - 63

Code: NCT06389136·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sites in New Haven, Middlebury +24 more locations

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 18 - 65

Code: NCT07161037·Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

Assessment of CCM in HF With Higher Ejection Fraction

for Heart Failure

Sites in Hartford, Danbury +74 more locations

Sponsor: Impulse Dynamics

Sex: All·Age: 18+

Code: NCT05064709·Recruiting·Listed Oct 2021

Apply to this trial

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

for Heart Failure

Drug: Empagliflozin

Sites in Bridgeport +94 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06424288·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

for Acute Myeloid Leukemia (AML)

Sites in New Haven, Hartford +40 more locations

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT07007312·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

Sites in New Haven, Norwalk +63 more locations

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

for Osteoarthritis, Knee

Sites in Hamden +40 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05986292·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

Sites in New Haven, Stamford +40 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

for Breast Neoplasms

Sites in New Haven, Hartford +37 more locations

Sponsor: Natera, Inc.

Sex: All·Age: 18+

Code: NCT07214532·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

Sites in New Haven, Hartford +132 more locations

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

for Prostate Cancer Metastatic

Sites in New Haven +30 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136624·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

for Metastatic Colorectal Cancer

Sites in New Haven +19 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT04929223·Phase 1·Recruiting·Listed Jun 2021

Apply to this trial

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

for Advanced Solid Tumor

Sites in New Haven +23 more locations

Sponsor: Synthekine

Sex: All·Age: 18+

Code: NCT05098132·Phase 1, Phase 2·Recruiting·Listed Oct 2021

Apply to this trial

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

for High Risk Cardiovascular Disease

Drug: Zilebesiran

Sites in Waterbury, Bridgeport +259 more locations

Sponsor: Alnylam Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07181109·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

for Migraine

Drug: Ubrogepant

Sites in Stamford +90 more locations

Sponsor: AbbVie

Sex: All·Age: 6 - 17

Code: NCT05125302·Phase 3·Recruiting·Listed Nov 2021

Apply to this trial

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

for Mantle Cell Lymphoma

Drug: Sonrotoclax

Sites in New Haven +40 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06742996·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

for Non-Small Cell Lung Cancer

Drug: Divarasib

Sites in Hartford +49 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06793215·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

for Metastatic Breast Cancer

Drug: Zongertinib

Sites in New Haven +25 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06324357·Phase 1, Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

for Chronic Lymphocytic Leukemia

Drug: Sonrotoclax

Sites in New Haven, Norwich +33 more locations

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06943872·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

for Geographic Atrophy

Sites in Greenwich +52 more locations

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: All ages

Code: NCT06779773·Recruiting·Listed Jan 2025

Apply to this trial

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

for Crohn's Disease

Sites in New Haven, Danbury +54 more locations

Sponsor: AbbVie

Sex: All·Age: 18 - 75

Code: NCT06548542·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for Carcinoma, Non-Small-Cell Lung

Drug: Intismeran autogene

Sites in New Haven, Norwich +46 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

for Depressive Disorder, Major

Drug: Seltorexant

Sites in Farmington +42 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18 - 74

Code: NCT06559306·Phase 3·Recruiting·Listed Aug 2024

Apply to this trial

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

for Episodic Migraine

Drug: Xeomin

Sites in New Haven, Stamford +44 more locations

Sponsor: Merz Therapeutics GmbH

Sex: All·Age: 18+

Code: NCT07018700·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

for Chronic Migraine

Drug: Xeomin

Sites in New Haven, Stamford +45 more locations

Sponsor: Merz Therapeutics GmbH

Sex: All·Age: 18+

Code: NCT07018713·Phase 3·Recruiting·Listed Jun 2025

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

for Ovarian Cancer

Sites in New Haven +31 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06824467·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

for Geographic Atrophy (GA)

Sites in Waterford +52 more locations

Sponsor: ONL Therapeutics

Sex: All·Age: 55+

Code: NCT06659445·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

for Crohn's Disease

Drug: Ustekinumab

Sites in Hamden +41 more locations

Sponsor: Takeda

Sex: All·Age: 18 - 70

Code: NCT06045754·Phase 4·Recruiting·Listed Sep 2023

Apply to this trial

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

for Non Small Cell Lung Cancer

Sites in Stamford +43 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312137·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

for Bronchiectasis

Sites in North Haven +56 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 12+

Code: NCT06872892·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Daratumumab

Sites in New Haven, Farmington +64 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05552222·Phase 3·Recruiting·Listed Sep 2022

Apply to this trial